Amnon Schlegel
Endocrinology, Diabetes & Metabolism · Sandy, UTNPI 1093910796
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.9% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,018 and has fallen 98.6% since, to $14 in 2025. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in UT, where the typical reported total is $3,842.
Across 64 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$228
- Novartis$153
- Abbott$122
- Lilly USA, LLC$88
- AbbVie$63
- Boehringer Ingelheim$61
- plus $348 from 13 others
Across 1 payment — averaging $56,346 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tandem Diabetes Care, Inc.$56K
What the payments were for
- Food & beverage$1,05299%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 14 | $228 |
| Novartis | 4 | $153 |
| Abbott | 11 | $122 |
| Lilly USA, LLC | 6 | $88 |
| AbbVie | 4 | $63 |
| Boehringer Ingelheim | 3 | $61 |
| Novo Nordisk | 4 | $56 |
| Medtronic | 3 | $47 |
| Amryt Pharma Holdings Ltd | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Xeris Pharmaceuticals, Inc. | 2 | $29 |
| Antares Pharma, Inc. | 2 | $27 |
| Travere Therapeutics, Inc. | 1 | $25 |
| Sanofi | 1 | $20 |
| BD | 1 | $20 |
| AstraZeneca | 1 | $17 |
| Amgen | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Tandem Diabetes Care, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$111
How this compares
$1,064 in reported general payments places this provider in the 40th percentile of 38 endocrinology, diabetes & metabolism providers in Utah.
See all endocrinology, diabetes & metabolism providers in Utah →
Other endocrinology, diabetes & metabolism in Sandy
- Timothy GrahamSandy$90K
- Richard CannonSandy$5K
- Eliot BrintonSalt Lake City$733K
- Claudia FishPark City$286K
- Alireza Falahati-NiniSalt Lake City$241K
- Steven BrownLayton$105K
- Jack WahlenOgden$70K
- Mohammed NizamProvo$54K
- Shahzad AhmadSalt Lake City$25K
- Priya KrishnamurthySt George$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.